The constitutive activation of the AKT signaling pathway negatively influences the response to therapeutic treatments, correlates with drug resistance and is associated with a poor prognosis for ALL patients [9,10,11]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.